Prostatype Genomics AB
6 Jul - 20 Jul 2022Rights issue
Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype.
By giving a comprehensive assessment of the aggressiveness of the prostate cancer, Prostatype helps clinicians and patients to make correct treatment decisions. Over and under treatment of prostate cancer can be minimized, the quality of life for the patient improved and money can be saved for the health care sector.
Read more at the company's website
The offer in summary
Record date: 30 June 2022
Subscription period: 6 July - 20 July 2022
Subscription rights: Anyone who were shareholder in the Company on the record date of June 30, 2022 has a preferential right to subscribe for units in the rights issue in relation to previous holdings, whereby one (1) existing share gives one (1) unit rights. Thirty seven (37) unit rights entitle to subscribe for one (1) new unit.
Price: 55.10 SEK per unit
The offer: 408 205 units
Trading with rights: 6 July - 15 July 2022
Market Place : Nasdaq First North Growth Market
Financial advisor: Sedermera Corporate Finance
Subscribe through Avanza here
Subscribe through Nordnet here
